Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Lakefront Biotherapeutics NV's 3-1 Month Momentum % is N/A%.
The industry rank for Lakefront Biotherapeutics NV's 3-1 Month Momentum % or its related term are showing as below:
GLPGF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.01 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Lakefront Biotherapeutics NV 3-1 Month Momentum % Related Terms
GLPGF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (GLPGF) has a 3-1 Month Momentum % of N/A% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lakefront Biotherapeutics NV and its competitors. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #312 out of 1386 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Lakefront Biotherapeutics NV's 3-1 Month Momentum % too high?
Lakefront Biotherapeutics NV's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #312 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #312 out of 1386 companies for 3-1 Month Momentum %. This places Lakefront Biotherapeutics NV in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (GLPGF) is currently considered Possible Value Trap. The stock's GF Value™ is $104.17, compared to a current price of $26.24 — trading 74.8% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Lakefront Biotherapeutics NV's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current 3-1 Month Momentum % is N/A% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $26.24 is trading 74.8% below its estimated GF Value™ of $104.17.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for GLPGF:
3-1 Month Momentum %: N/A%
GF Value™: $104.17 vs. price of $26.24 (74.8% below fair value)
No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
54GF Score
Get the complete analysis for GLPGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLPGF has been successfully added to your 
